Use our chat feature to speak with one of our expert consultants who can help you identify if medical cannabis can help you.
5 min read
Sarah Sinclair
While awareness of medical cannabis has grown in recent years, there remains a huge knowledge gap when it comes to healthcare professionals and their understanding of this treatment.
In September, Drug Science, the UK’s independent charity for drug reform, published a new report exploring the awareness and attitudes of healthcare professionals around medical cannabis. We take a closer look at the findings and potential implications.
Even though medical cannabis has been legal in the UK for almost six years, there is still a lack of awareness and understanding about its therapeutic use, particularly among healthcare professionals.
Out of 40,000 specialist clinicians who are eligible to prescribe cannabis in the UK, only around 100 (0.25%) actually do. And even though the number of patients accessing private prescriptions has increased significantly, there are still fewer than five obtained through the NHS.
There are many reasons for this, such as the fact that doctors are generally not taught about the endocannabinoid system (ECS) in medical school and the fact that cannabis has for decades been associated with illegal drug use.
But it’s crucial that healthcare professionals are educated and have some level of understanding of cannabis-based medicines, to not only increase access, but to avoid stigmatising patients who choose this treatment option.
The Drug Science report surveyed 72 healthcare professionals from various sectors to explore their perspectives towards medical cannabis. Questions addressed their perceived knowledge, confidence, and concerns about prescribing, alongside their personal experiences and attitudes towards legalisation.
One of the key findings in this paper was that a significant proportion of healthcare professionals felt they lacked sufficient knowledge about medical cannabis. Of those who completed the survey, just over half (55.6%) had undergone training related to medical cannabis.
The researchers’ analysis revealed that those who had received training had greater perceived knowledge of medical cannabis.
Healthcare professionals who had received training were more confident in prescribing medical cannabis and demonstrated increased recognition of its potential benefits in clinical practice. These professionals also demonstrated a deeper understanding of the legal and regulatory framework surrounding its use, as well as the conditions it can be used to treat.
Attitudes among healthcare professionals varied in this survey, with some expressing caution due to the perceived lack of robust clinical evidence and concerns over safety. However, those with formal training or experience in prescribing were more likely to view it as a viable treatment option, especially for conditions that have not responded well to conventional treatments.
The healthcare professionals that took part cited several barriers to the wider prescribing of medical cannabis. These included insufficient evidence, restrictive prescribing guidelines, and concerns about potential side effects or interactions with other medications.
Some professionals mentioned the stigma attached to cannabis, both from within the medical community and from patients, as a hindrance to wider adoption.
Barriers to prescription and the cost of medical cannabis were the most endorsed concerns among both groups.
While this report offers some valuable insights into the perspectives of healthcare professionals, there are a number of limitations to consider.
As well as the small sample size, which may not fully represent the broader spectrum of UK healthcare professionals, the study relied on self-reported data, which can introduce biases such as overestimation of knowledge or confidence.
The researchers also didn’t differentiate between licensed and unlicensed products, instead the term ‘medical cannabis’ is used to encompass a wide variety of forms and concentrations of active ingredients, which could have affected the results.
In the six years since medical cannabis was legalised in the UK, other studies have carried out similar analyses. The findings broadly highlight a general lack of awareness and education on medical cannabis among healthcare professionals, both in the UK and internationally.
In a recent study, exploring the experience of medical cannabis patients, participants reported that their NHS healthcare providers ‘lack knowledge’ of the legality of cannabis medicines. While some were ‘curious and keen to learn’ others displayed ‘stigmatising attitudes’ towards prescribed patients.
Meanwhile, the Known Unknowns of Medical Cannabis, report published in December 2022 by Volteface, shed some light on what healthcare professionals perceived to be the main challenges, identifying issues including lack of governance, insufficient high quality evidence and doctors not being educated or supported in prescribing.
But some surveys have suggested an increasing interest and gradual shift in attitudes, with around three-quarters of GPs saying they were 'open-minded’ about prescribing cannabis-based medicines back in 2021. In a smaller survey in 2023, 65% of healthcare professionals said they thought medical cannabis should be available on the NHS when conventional treatments have failed.
While more extensive research is needed to draw definitive conclusions, the recent Drug Science report provides a snapshot of healthcare professionals' knowledge and attitudes toward medical cannabis in the UK.
With increasing patient interest in cannabis-based treatments, it is essential that healthcare professionals have the adequate training to provide evidence-based advice and care and avoid perpetuating stigma. The positive link between training and confidence in prescribing suggests that investing in education could lead to more widespread and effective use of medical cannabis in clinical practice.
To learn more about medical cannabis and the conditions it can help treat, visit Releaf’s blog and education section.
It is important to seek medical advice before starting any new treatments. The patient advisors at Releaf are available to provide expert advice and support. Alternatively, click here to book a consultation with one of our specialist doctors.
Get comprehensive care, convenience, and confidence with an all-in-one treatment plan.
Am I eligible?Sarah, a distinguished journalist with over a decade in publishing and communications, now excels in cannabis health and policy journalism in the UK, advocating for informed health decisions through her award-winning work.
All of our articles are written by medical cannabis experts, guided by strict sourcing guidelines, and reference peer-reviewed studies and credible academic research. Our expert clinical team and compliance specialists provide valuable insights to ensure accuracy when required. Learn more in our editorial policy.
Need more help?
November is National COPD Awareness Month, a time dedicated to raising awareness of Chronic Obstructive Pulmonary Disease (COPD) and the prevention and treatment of chronic lung disease. In honour of this important event, we’re taking a closer look at the relationship between medical cannabis and chronic lung disease and answering the question: “Can I vape medical cannabis if I have COPD?”
Emily Ledger
Medical cannabis treatment is quite an individual process, which means there is no one-size-fits-all answer to the question of how often you should see your doctor. Each and every patient we see here at Releaf responds at least slightly differently to their treatment protocol. This is the main reason our world-class clinical team takes such a personalised approach to each patient's care and why it is essential that all patients see their doctor regularly.
Sam North
Disability History Month, taking place from 14 November— 20 December highlights the history of the equality and human rights struggles of disabled individuals in the UK.
Sarah Sinclair
